Navigation Links
Portola Pharmaceuticals Presents Positive Phase I Data of Its ADP,Receptor Antagonist at the American College of Cardiology

NEW ORLEANS, March 28, 2007 /PRNewswire/ -- Portola Pharmaceuticals, Inc. presented Phase I data of its ADP receptor antagonist at the of Cardiology's (ACC) 56th Annual Scientific Session this week. Portola's reversible antiplatelet compound, PRT060128, appeared safe and well-tolerated in this study and achieved high-level platelet inhibition.

Portola presented the data in a poster session titled "First in Human Experience with PRT060128, a New Direct-acting, Reversible P2Y(12) Inhibitor for IV and Oral Use" which describes the single ascending dose (SAD) study of the oral formulation of PRT060128. In this study, dose dependent and full inhibition of ADP-induced platelet aggregation was achieved. In addition, following administration of PRT060128, inhibition of platelet aggregation was fully reversed within 24 hours post dosing. All doses of PRT060128 were well tolerated. There were no serious adverse events and no discontinuations due to an adverse event.

"Successful results from both our Phase I oral and intravenous studies build a strong foundation for advancing PRT060128 in the clinic," said Dan Gretler, MD, Portola's vice president of Clinical Development and Regulatory Affairs. "We will initiate our Phase II clinical program later this year to further study the differentiated properties of our ADP receptor antagonist."

Portola's ADP Receptor Antagonist

PRT060128 is an antiplatelet drug that is the only intravenous (IV) and oral ADP receptor antagonist in clinical development. Portola believes that this compound may provide significant clinical benefit through immediate, high-level platelet inhibition in the acute setting and a seamless transition to predictable, reversible platelet inhibition in the chronic setting. Portola has studied this compound in a robust Phase I clinical development program including single ascending dose and multiple ascending dose studies with the oral formulation and a single ascending dose study with the IV formulation. Based on positive results from these studies, Portola intends to initiate its Phase II program in 2007.

About Portola Pharmaceuticals, Inc.

Portola Pharmaceuticals, Inc. is a private biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapeutics for acute and chronic cardiovascular and vascular disease. Portola is currently developing two clinical stage antithrombotics. Portola's lead compound, PRT054021, is an oral Factor Xa inhibitor for the prevention of venous thromboembolism after orthopedic surgery, for stroke prevention in patients with atrial fibrillation, and for secondary prevention of myocardial infarction (MI) and stroke. Portola's second compound, PRT060128, is an oral and intravenous ADP receptor antagonist for patients with acute coronary syndrome, for the prevention of cardiovascular events in patients undergoing percutaneous coronary intervention and for secondary prevention of MI and stroke.

CONTACT: Ember Garrett of Porter Novelli Life Sciences, +1-619-849-5383,or , for Portola Pharmaceuticals egarrett@pnlifesciences.com

Web site: http://www.portola.com/

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Related medicine technology :

1. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
2. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
3. Portola Pharmaceuticals Announces Positive Phase II Results for PRT054021 for Prevention of Venous Thromboembolism Following Total Knee Replacement Surgery
4. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
7. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
8. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
9. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
10. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
11. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... DIEGO , April 19, 2017  Sorrento ... an antibody-centric, clinical-stage biopharmaceutical company developing new treatments ... announced the closing of its previously announced underwritten ... stock at a public offering price of $2.00 ... and estimated offering expenses payable by Sorrento.  The ...
(Date:4/19/2017)... 19, 2017  SARES•REGIS Group leased the first ... at Conejo Spectrum Business Park in ... Biotherapeutics, Inc. , a biopharmaceutical company developing meaningful ... that have been underserved by scientific innovation, with ... cancer, autoimmune and infectious disease. Before ...
(Date:4/18/2017)... Research and Markets has announced the addition ... their offering. ... devices market to grow at a CAGR of 6.35% during the ... 2017-2021, has been prepared based on an in-depth market analysis with ... its growth prospects over the coming years. The report also includes ...
Breaking Medicine Technology:
(Date:4/24/2017)... ... April 24, 2017 , ... My T Chai, a South African company ... available for purchase on RevNutrition.com, a popular website specializing in sales of nutritional products. ... in ancient India and Siam. It spread across Asia and Africa quickly, and today ...
(Date:4/24/2017)... HOUSTON, TEXAS (PRWEB) , ... April 24, 2017 ... ... service (SaaS) based healthcare compliance and credentialing solutions, today announced that Kyle Allain ... Allain leads symplr’s Cactus Provider Management sales and operations, including provider, payor and ...
(Date:4/24/2017)... ... April 24, 2017 , ... In 2017, up to ... approximately 25,000 of them will be malignant.(1) As research into precision medicine continues, ... healthcare model in the diagnosis and treatment of brain tumors. Healthcare facilities that ...
(Date:4/24/2017)... , ... April 24, 2017 , ... Rod Burkett, CEO ... Housing News website. , Rod has been at the forefront of Gardant since it ... As CEO, Rod has overseen the opening of more than 40 new senior living ...
(Date:4/24/2017)... ... ... As a former supermodel known for her timeless beauty, Joan Severance knows ... is that she put all the words in her new book, "Manifest Your Mate: ... and sparkling sense of humor have inspired her to write a book on how ...
Breaking Medicine News(10 mins):